Cost effectiveness of cannabis is vastly understudied and can be a real burden to many patients that require higher doses. This study was published in March 2021 in Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders and concluded that:
"medical cannabis oils and soft gels at both the minimal and maximal recommended daily doses were cost-effective compared to all current knee pain therapies at the lowest WTP (willingness to pay) threshold. Dried flowers were only cost-effective up to a certain dosage (0.75 and 1 g/day)."
A link to the research is here.